Clinical Trials
6 trialsNCT01839487 2020-07-20
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Halozyme Therapeutics
Phase 2 Completed
NCT04058964 2020-03-13
Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04134468 2020-01-31
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Withdrawn
NCT02487277 2020-01-02
PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
University of California, San Francisco
Phase 2 Terminated
NCT03634332 2019-05-07
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
Pancreatic Cancer Research Team
Phase 2 Unknown
NCT02910882 2019-04-11
HALO-IST
Scripps Health
Phase 2 Terminated